IR
Superintel
OverviewMarketsWatchlist
© 2026 IR SuperintelMethodologyContact

Obsidian Therapeutics Inc (OBX)

CUSIP: 67448A106 | NYSE | 4 institutional holders

Quarters

Q3 2026
CompareDetailedHistoricalFundsOptions13D/13GPeersTargetingTrading SummaryProfile

Beneficial Ownership — 13D / 13G

Full history →

5%+ stakes reported outside the quarterly cycle. A 13D is due within five business days of the event below, so these figures lead the holders table until the filer's next 13F catches up to them.

HolderShares% of ClassChangeEvent Datevs 13F
13GParadigm BioCapital Advisors LP
with Paradigm BioCapital International Fund Ltd.
4,101,5766.6%New 5%+ stakeSep 28, 2026No 13F filer matched
13GDeep Track Capital, LP
with Deep Track Biotechnology Master Fund, Ltd., Deep Track Special Opportunities Fund, Lp.

Institutional Holders — Q3 2026

Revelation Capital Management, LLC428,346
73.4% of portfolio›$5.9M
Bank of New York Mellon Corp11,163
0.0% of portfolio›$153.3K
Citigroup Inc419
0.0% of portfolio›$5.8K
SBI Securities Co., Ltd.1
0.0% of portfolio›$14
StyleTurnoverLocationFiled
Revelation Capital Management, LLC
428,346$5.9M73.4%CoreVery LowSausalito, CA2026-11-02
Bank of New York Mellon Corp
11,163$153.3K0.0%CoreLowNew York, NY2026-11-05
Citigroup Inc
419$5.8K0.0%CoreMediumNew York, NY2026-11-04
SBI Securities Co., Ltd.
1$140.0%Agg GrowthLowTokyo, Mexico2026-10-22
3,315,605
5.4%
New 5%+ stake
Aug 4, 2026
No 13F filer matched
13GRA Capital Management, L.P.
with RA Capital Healthcare Fund, L.P.
5,957,1039.7%New 5%+ stakeAug 3, 2026Not yet in a 13F
13GNovo Holdings A/S3,123,9925.1%New 5%+ stakeAug 3, 2026Not yet in a 13F
13GAtlas Venture Associates X, L.P.
with Atlas Venture Associates Opportunity I, L.P., Atlas Venture Associates Opportunity I, LLC, Atlas Venture Opportunity Fund I, L.P., +6 more
2,642,5874.3%Newly reportedAug 3, 2026No 13F filer matched
13GParadigm BioCapital Advisors LP4,101,576
6.6% of class · Sep 28, 2026New 5%+ stake
with Paradigm BioCapital International Fund Ltd.
No 13F filer matched
13GDeep Track Capital, LP3,315,605
5.4% of class · Aug 4, 2026New 5%+ stake
with Deep Track Biotechnology Master Fund, Ltd., Deep Track Special Opportunities Fund, Lp.
No 13F filer matched
13GRA Capital Management, L.P.5,957,103
9.7% of class · Aug 3, 2026New 5%+ stake
with RA Capital Healthcare Fund, L.P.
Not yet in a 13F
13GNovo Holdings A/S3,123,992
5.1% of class · Aug 3, 2026New 5%+ stake
Not yet in a 13F
13GAtlas Venture Associates X, L.P.2,642,587
4.3% of class · Aug 3, 2026Newly reported
with Atlas Venture Associates Opportunity I, L.P., Atlas Venture Associates Opportunity I, LLC, Atlas Venture Opportunity Fund I, L.P., +6 more
No 13F filer matched